In contrast, total cholesterol or LDL-C levels showed no significant change in the statin-treated group, suggesting that PCSK9 inhibitors might be effective and safe alternatives for treating hypercholesterolemia associated with refractory nephrotic syndrome. Here, PCSK9 is linked to nephrotic syndrome.